"Takeda is paying Finch Therapeutics $10 million upfront for exclusive, global rights to develop and commercialize the latter’s inflammatory bowel disease (IBD) candidate, FIN-524, together with rights to follow-on products for IBD indications.

Under terms of the deal, Finch will be eligible for undisclosed development, regulatory, and commercialization milestones, plus future tiered royalties. The firms have written-in the option to extend their collaboration to other, related indications."